Seasonal Influenza - Pipeline Review, H1 2014

Seasonal Influenza - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Seasonal Influenza - Pipeline Review, H1 2014’, provides an overview of the Seasonal Influenza’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Seasonal Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seasonal Influenza and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Seasonal Influenza
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Seasonal Influenza and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Seasonal Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Seasonal Influenza pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Seasonal Influenza
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Seasonal Influenza pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Seasonal Influenza Overview 11
Therapeutics Development 12
Pipeline Products for Seasonal Influenza - Overview 12
Pipeline Products for Seasonal Influenza - Comparative Analysis 13
Seasonal Influenza - Therapeutics under Development by Companies 14
Seasonal Influenza - Therapeutics under Investigation by Universities/Institutes 17
Seasonal Influenza - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Seasonal Influenza - Products under Development by Companies 22
Seasonal Influenza - Products under Investigation by Universities/Institutes 24
Seasonal Influenza - Companies Involved in Therapeutics Development 25
GlaxoSmithKline plc 25
Lentigen Corporation 26
Celltrion, Inc. 27
Liquidia Technologies, Inc. 28
Novartis AG 29
Novavax, Inc. 30
Crucell N.V. 31
BioDiem Ltd 32
Eurocine Vaccines AB 33
Colby Pharmaceutical Company 34
Bionor Pharma ASA 35
FluGen, Inc. 36
TechnoVax, Inc. 37
Theraclone Sciences, Inc. 38
NanoBio Corporation 39
Protein Sciences Corporation 40
Vaxart, Inc. 41
VBI Vaccines 42
AIMM Therapeutics B.V. 43
Cilian AG 44
AmVac AG 45
TSRL, Inc. 46
Vaxine Pty Ltd 47
AltraVax Inc. 48
Big DNA Ltd. 49
PeptiVir, Inc. 50
Inhibikase Therapeutics, Inc. 51
Codagenix, Inc. 52
Lakewood-Amedex Inc. 53
Seasonal Influenza - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Combination Products 55
Assessment by Target 56
Assessment by Mechanism of Action 58
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 65
influenza vaccine, surface antigen, inactivated, adjuvanted with MF59C.1 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
influenza vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
GSK-2321138A - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
influenza vaccine, surface antigen, inactivated, adjuvanted with MF59C.1 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
FluCell - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Trivalent Seasonal Influenza VLP Vaccine - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Live Attenuated Influenza Vaccine - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
JVRS-100 + Fluzone - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
H1N1-2009 VLP Vaccine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
TCN-032 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Quadrivalent Seasonal Influenza Virus-Like Particle Vaccine - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Seasonal Flu Vaccine - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Nasal Influenza Vaccine - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
LIQ-001 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Trivalent Seasonal Influenza VLP Vaccine - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
influenza vaccine - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
NB-1008 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
CT-P27 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Flu-Virus Program - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
VXAA-1.1 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
LG-811 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
influenza vaccine - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
TVX-001 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Drug For Influenza Prophylaxis - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Vacc-Flu - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Monoclonal Antibodies Targeting Hemagglutinin - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Variosite Flu Vaccine - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
AMV-401 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
CiFlu - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Flu-Virus Bispecific Program - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
TSR-026 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Seasonal Influenza Vaccine - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
IKT-041 - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Seasonal Trivalent Influenza Vaccine - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
PVI-1000 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Influ-nRNA - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
A-06 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
BDNA-002 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
CT-P25 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Universal Vaccines For Seasonal And Pandemic Influenza - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
TSR-462 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
TCN-032 - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
PAL-FLU Vaccine - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Seasonal Influenza - Recent Pipeline Updates 125
Seasonal Influenza - Dormant Projects 135
Seasonal Influenza - Discontinued Products 136
Seasonal Influenza - Product Development Milestones 137
Featured News & Press Releases 137
Jan 15, 2014: Astellas and UMN Announce Summary Results in Phase III Clinical Trials of Seasonal Flu Vaccine ASP7374 137
Apr 03, 2013: GSK's Four-strain Seasonal Influenza Vaccine Receives Marketing Authorization In Germany And UK 137
Mar 11, 2013: Astellas Pharma And UMN Pharma Announce Summary Results For Phase III Clinical Trial Of Recombinant Seasonal Influenza HA Vaccine ASP7374 139
Feb 19, 2013: BARDA Continues Support For Protein Sciences's Flublok Influenza Vaccine 139
Jan 24, 2013: Novavax Reports Completion Of In-process Review Of Its Influenza Vaccine Contract By BARDA 139
Dec 11, 2012: Astellas And UMN Pharma Complete Administration Of Phase III Clinical Trials Of Seasonal Flu Vaccine ASP7374 140
Sep 10, 2012: Novavax Delays Testing On New Experimental Flu Vaccine 140
Jul 24, 2012: NOVAVAX Provides Update on Influenza Programs 141
Feb 23, 2012: CSL Biotherapies's Fluvax Causes Febrile Adverse Events In Children 143
Oct 10, 2011: CILIAN AG: Major Milestone In The Production of Recombinant Influenza Vaccine 143
Appendix 144
Methodology 144
Coverage 144
Secondary Research 144
Primary Research 144
Expert Panel Validation 144
Contact Us 145
Disclaimer 145

List of Tables
Number of Products under Development for Seasonal Influenza, H1 2014 12
Number of Products under Development for Seasonal Influenza - Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 15
Number of Products under Development by Companies, H1 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Late Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Development, H1 2014 20
Comparative Analysis by Unknown Stage Development, H1 2014 21
Products under Development by Companies, H1 2014 22
Products under Development by Companies, H1 2014 (Contd..1) 23
Products under Investigation by Universities/Institutes, H1 2014 24
Seasonal Influenza - Pipeline by GlaxoSmithKline plc, H1 2014 25
Seasonal Influenza - Pipeline by Lentigen Corporation, H1 2014 26
Seasonal Influenza - Pipeline by Celltrion, Inc., H1 2014 27
Seasonal Influenza - Pipeline by Liquidia Technologies, Inc., H1 2014 28
Seasonal Influenza - Pipeline by Novartis AG, H1 2014 29
Seasonal Influenza - Pipeline by Novavax, Inc., H1 2014 30
Seasonal Influenza - Pipeline by Crucell N.V., H1 2014 31
Seasonal Influenza - Pipeline by BioDiem Ltd, H1 2014 32
Seasonal Influenza - Pipeline by Eurocine Vaccines AB, H1 2014 33
Seasonal Influenza - Pipeline by Colby Pharmaceutical Company, H1 2014 34
Seasonal Influenza - Pipeline by Bionor Pharma ASA, H1 2014 35
Seasonal Influenza - Pipeline by FluGen, Inc., H1 2014 36
Seasonal Influenza - Pipeline by TechnoVax, Inc., H1 2014 37
Seasonal Influenza - Pipeline by Theraclone Sciences, Inc., H1 2014 38
Seasonal Influenza - Pipeline by NanoBio Corporation, H1 2014 39
Seasonal Influenza - Pipeline by Protein Sciences Corporation, H1 2014 40
Seasonal Influenza - Pipeline by Vaxart, Inc., H1 2014 41
Seasonal Influenza - Pipeline by VBI Vaccines, H1 2014 42
Seasonal Influenza - Pipeline by AIMM Therapeutics B.V., H1 2014 43
Seasonal Influenza - Pipeline by Cilian AG, H1 2014 44
Seasonal Influenza - Pipeline by AmVac AG, H1 2014 45
Seasonal Influenza - Pipeline by TSRL, Inc., H1 2014 46
Seasonal Influenza - Pipeline by Vaxine Pty Ltd, H1 2014 47
Seasonal Influenza - Pipeline by AltraVax Inc., H1 2014 48
Seasonal Influenza - Pipeline by Big DNA Ltd., H1 2014 49
Seasonal Influenza - Pipeline by PeptiVir, Inc., H1 2014 50
Seasonal Influenza - Pipeline by Inhibikase Therapeutics, Inc., H1 2014 51
Seasonal Influenza - Pipeline by Codagenix, Inc., H1 2014 52
Seasonal Influenza - Pipeline by Lakewood-Amedex Inc., H1 2014 53
Assessment by Monotherapy Products, H1 2014 54
Assessment by Combination Products, H1 2014 55
Number of Products by Stage and Target, H1 2014 57
Number of Products by Stage and Mechanism of Action, H1 2014 59
Number of Products by Stage and Route of Administration, H1 2014 61
Number of Products by Stage and Molecule Type, H1 2014 64
Seasonal Influenza Therapeutics - Recent Pipeline Updates, H1 2014 125
Seasonal Influenza - Dormant Projects, H1 2014 135
Seasonal Influenza - Discontinued Products, H1 2014 136

List of Figures
Number of Products under Development for Seasonal Influenza, H1 2014 12
Number of Products under Development for Seasonal Influenza - Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Clinical Stage Development, H1 2014 19
Comparative Analysis by Early Stage Products, H1 2014 20
Comparative Analysis by Unknown Stage Development, H1 2014 21
Assessment by Monotherapy Products, H1 2014 54
Number of Products by Top 10 Target, H1 2014 56
Number of Products by Stage and Top 10 Target, H1 2014 57
Number of Products by Top 10 Mechanism of Action, H1 2014 58
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 59
Number of Products by Top 10 Route of Administration, H1 2014 60
Number of Products by Stage and Top 10 Route of Administration, H1 2014 61
Number of Products by Top 10 Molecule Type, H1 2014 62
Number of Products by Stage and Top 10 Molecule Type, H1 2014 63